Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
March 15, 2024
RegMed Investors (RMi) Closing Bell: triple witching Friday
March 1, 2024
RegMed Investors (RMi) Closing Bell: another knee-jerk reaction but, to our advantage
February 29, 2024
RegMed Investors (RMi) Closing Bell: investor jitters
February 28, 2024
RegMed Investors (RMi) Closing Bell: run from sector highs to cash as a portfolio value preservation strategy
February 23, 2024
RegMed Investors’ (RMi) pre-open: caution and watch-out for re-calibrations
February 21, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy equities closes barely positive
February 12, 2024
RegMed Investors (RMi) Closing Bell: testing, testing, testing the flight plan request
February 9, 2024
RegMed Investors (RMi) Closing Bell: hang-on to reward prospects for a while
February 2, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector fluctuates what’s different?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors